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Background: We study the human serum albumin (HSA) protein-CuO nanoparticle interaction to identify
the speciﬁc binding site of protein with CuO nanoparticles by molecular docking and compared it with
HSA-TiO2 nanoparticle interaction.
Methods: The protein structural data that was obtained using Autodock 4.2.
Results: In case of CuO np-HSA interaction, the distances from the centre of Subdomain IIIA to Arg-472 is
2.113 Å and Lys 475, Glu 492, Ala 490, Cys 487, Ala 490 are the bound neighbouring residues with Lys 475,
Glu 492 at aliphatic region. The binding energy generated was 1.64 kcal mol1. However, for TiO2
nanoparticle, the binding region is surrounded by Arg 257, Ala 258, Ser 287, His 288, Leu 283, Ala 254, Tyr
150 (subdomain II A) as neighbouring residue. Moreover, Glu 285, Lys 286 forms aliphatic grove for
TiO2-HSA, Ser-287 at the centre region form hydrogen bond with nanoparticle and Leu 283, Leu 284
forming hydrophopobic grove for TiO2 nanoparticle-HSA interaction. The binding energy generated was
2.47 kcal mol1.
Conclusions: Analysis suggests that CuO bind to suldow site II i.e subdomain III A of HSA protein where as
TiO2 nanoparticle bind to suldow site I i.e subdomain IIA of HSA protein.
General signiﬁcance: The structural information that derives from this study for CuO and TiO2 nano-
particles may be useful in terms of both high and low-afﬁnity binding sites when designing these na-
noparticles based drugs delivery system.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Human serum albumin (HSA) is one of the important transport
proteins in the human blood and can bind to any ligand that in-
jected into blood stream thus play important role in drug delivery
system. Structurally, a single polypeptide chain of HSA consists of
585 amino acids. HSA consists of three homologous domains (I, II,
and III) and each comprised of subdomain A and B. The sub-
domains IIA and IIIA of HSA consists of high afﬁnity ligand binding
sites and is referred as Sudlow's site I and II, respectively [1,2].
The high surface areas and unusual crystal morphologies endue
CuO NPs with antimicrobial activity. CuO NPs are most frequently
used as antimicrobial (antiviral, antibacterial, antifouling, anti-
fungal), antibiotic treatment alternatives, nanocomposite coating,
catalyst, lubricants. Also, used in applications like gas sensors,
solar energy conversion, electrode material in lithium ion bat-
teries, as ﬁeld emitter, and as a heterogeneous catalyst [3]. TiO2r B.V. This is an open access article
(S. Chibber).NPs drive a strong interest, subsequently intensive experimental
and theoretical studies, owing to its unique photocatalytic prop-
erties, excellent biocompatibility, and high chemical stability. TiO2
NPs are used widely in biomedical applications that include the
photodynamic therapy for cancer treatment, drug delivery sys-
tems, cell imaging, biosensors for biological assay, and genetic
engineering. High physical and chemical stability of CuO and TiO2
nanoparticles renders their extreme use in catalytic applications
[4]. However, Nanotoxicology is come forth in the ﬁeld of tox-
icology to address the gaps in knowledge and adverse health ef-
fects associated with CuO and TiO2 nanomaterials. CuO NPs ex-
posure results in signiﬁcantly elevated level of antioxidant en-
zymes. CuO NPs has also been found to induce hepatotoxicity and
nephrotoxicity. CuO NPs can equally exhibit neurotoxicity and
genotoxicity [5–8]. TiO2 NPs has also been found to induced si-
milar toxicity but to lesser extent as compared to CuO NPs [9–12].
Thus, it is very important to understood interaction mechanism of
CuO NPs and TiO2 NPs with serum albumin and accordingly re-
duces CuO NPs and TiO2 NPs vulnerability in the system thereby
minimizing its toxic effects.under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Residual interactions at the HSA-CuO nanoparticle interface in HSA. Sche-
matic representations of different residues that are involve in binding with CuO
NPs and their distances obtained from central subdomain III A.
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understand its bioavailability, distribution, and elimination from
the body. HSA can bind a notable variety of drugs affecting their
delivery and efﬁcacy and ultimately altering the drug’s pharma-
cokinetic and pharmacodynamic properties. Additionally, HSA is
widely used in clinical assumptions as a drug delivery system due
to its potential for improving targeting while decreasing the side
effects of drugs. Nanoparticles such as CuO and TiO2 are widely
used in medical application such as drug delivery system [13,14].
Subsequently, the afﬁnity between HSA and nanoparticles as le-
gend becomes crucial interest to study in order to determine na-
noparticles binding potential with circulating protein. The binding
study conducted through molecular docking can help to infer the
duration of its half-life that consequently reveals the efﬁcacy of
nanomedication [1]. Drug delivery mechanism is propagated
through serum albumin. In order to introduce CuO NPs and TiO2
NPs in nanodelivery it is most worthy for the researchers to be
aware about interaction sites and the region involve in binding
with serum albumin so that nanoparticles itself may not become
inhibitor for the drug binding sites. Therefore, present study
conducted on the comparison of binding afﬁnity of serum albumin
with CuO and TiO2 nps. Thus, it may provide valuable information
concerning their therapeutic efﬁcacies.2. Methods
Molecular docking studies were carried out using AutoDock
4.2 tool to predict the preferred binding mode and binding sites of
TiO2 and CuO with HSA. The structure of TiO2 and CuO was drawn
using ACD/ChemSketch and its geometry was optimized by com-
bine use of Gaussian 03 program and Autodock 4.2. The crystal
structure of HSA (PDB ID: 1E7I) was obtained from Protein Data
Bank [15]. Before docking analysis Hetatm were removed from the
protein and the energy was minimized by SPDBV-Swiss-pdbviewer.
For docking calculations, Lamarckian genetic algorithms (LGA) were
used and grid parameters were set as 126126126, with a
spacing of 1 Å, in AutoDock 4.2. To determine the preferred binding
sites on HSA, TiO2 and CuO molecules were allowed to move within
the whole region of HSA via 50 runs to obtain the possible binding
gesture. The output from AutoDock was further analyzed with Py-
MOL and UCSF Chimera software package [16,17].3. Results
3.1. Different residues in HSA protein and their distances from
tryptophan in case of CuO np-HSA interaction
The preferable binding of CuO nanoparticles to HSA protein
obtained was through polar residue Arg 472 residue and through
Lys 475, Glu 492, Ala 490, Cys 487, Ala 490 bond formation. The
measured distances between the surfaces of the CuO np and Arg
residue (subdomain IIIA) site II obtained were 2.113 Å, 2.410 Å,
with Glu having 1.713 Å as shown in Fig. 1. Therefore, these sites
would be the probable binding sites of HSA with CuO
nanoparticles.
3.2. Geometrical accommodation and the chemical environment of
domain in HSA in case of CuO np-HSA binding
4 hydrogen bonds were predicted involving hydrogen atoms
from three different amino acid residues of HSA (Arg-472, Gln-492
and Ala 490) as showed in Fig. 2. Lys 475, Glu 492 residue are
charged grove of HSA bind with CuO nanoparticle as depicted
in Fig. 3.3.3. Different residues in HSA protein and their distances from sur-
face of TiO2 np-HSA interaction
The preferable binding of TiO2 nanoparticles to HSA protein
obtained was through polar hydrophilic amino acids Arg 257 re-
sidue and thorugh Ala 258, Ser 287, His 288, Leu 283, Ala 254, Tyr
150 form bond formation with TiO2 np. The measured distances
between the surfaces of the TiO2 np and Arg residue (subdomain II
A) obtained were 2.536 Å. However, 2.916 Å, 2.631 Å, 1.779 Å,
2.563 Å, 2.920 Å and 1.972 Å is the bond length with respective
amino acids of bound region as shown in Fig. 4. Therefore, these
sites would be the probable binding sites of HSA with TiO2
nanoparticle.
3.4. Geometrical accommodation and the chemical environment of
domain in HSA in case of TiO2 np-HSA binding
4 hydrogen bonds were predicted involving hydrogen atoms
from three different amino acid residues of HSA (Tyr 150, Ser-287
and Arg 257) as shown in Fig. 5. Leu 283, Leu 284, Glu 285, Lys 286
residue form hydrophobic pocket of HSA that bind with TiO2 na-
noparticle as depicted in Fig. 6.
3.5. Binding energy predicted for CuO np-HSA interaction and TiO2
np-HSA interaction
The predicted binding models of CuO with the lowest docking
energy (1.64 kcal mol1) at site II of HSA were used for binding
orientation analysis. Whereas, in case of TiO2 nanoparticle the
lowest docking energy obtained was 2.47 kcal mol1 (Table 1) at
the binding region.4. Discussion
Amino acid sequence of human serum albumin (HSA) consists of
18 tyrosines, 6 methionines, 1 tryptophan (Trp 214), 17 disulﬁde
bridges, and only one free thiol (Cys 34) residue. HSA comprises of
three homologous domains (I, II, and III) that assemble to form a
cordate molecule. The hydrophobic pockets at subdomains IIA and IIIA
is the main regions of ligand interaction with IIIA having the highest
afﬁnity for the interaction [2,18]. In our study the whole region of HSA
Fig. 2. Graphical representation of HSA-CuO nanoparticle complex. Hydrophobic moieties involve in interactions with CuO NPs are shown as graphical representation.
Fig. 3. Aliphatic region identiﬁcation of HSA-CuO nanoparticle interaction. The
surrounding residue of the binding region of HSA that forms grove with CuO NPs.
Fig. 4. Residual interactions at the HSA-TiO2 nanoparticle interface in HSA. Sche-
matic representations of different residues in HSA protein and their distances from
centre subdomain II A.
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nanoparticle for the autodock. Many ligands bind speciﬁcally to HSA,
either in site I (located at subdomain IIA) or in site II (located at
subdomain IIIA). In our case CuO bind to site II, subdomain III A and
TiO2 nanoparticle bind to site I located at subdomain II A.
The single tryptophan of HSA at residue 214 has been used
extensively for binding studies [19]. From the protein structural
data the distances from the centre of subdomain IIIA to Arg-472
(subdomain III A) was found to be 2.113 Å whereas on entering the
grid for TiO2 nanoparticle the region predicated by Autodock 4.2 is
Arg 257 (subdomain IIA) with bond length of 2.536 Å. The struc-
tural information that derives from this study for CuO and TiO2
may be useful for designing these nanoparticles based drug de-
livery system considering in terms of both high and low-afﬁnity
binding sites. This is helpful in order to avoid binding to HSA, or to
make use of its depot function for the delivery purpose.The attachment of CuO nanoparticles at the site II may be ex-
plained by considering the geometrical arrangement (Arg-472, Gln-
492 and Ala 490) surrounded by and the environment of charged
pocket Lys 475, Glu 492 of the domain (subdomain III A) in HSA.
However in case of TiO2 nanoparticle structural binding residue
involved were Arg 257, Ala 258, Ser 287, His 288, Leu 283, Ala 254,
Tyr 150 at the interior hydrophobic binding pocket and comprise
loop helix features of HSA at subdomain IIA. The other residues
which was docked were Ser-287, Leu 283, Leu 284, Glu 285, Lys 286
this show that TiO2 np interact with both the cluster of polar re-
sidues at suldow site II (subdomain II A) of HSA protein [13]. Upon
CuO nanoparticle binding, Lys 475 from subdomain III A moves to
interact with the Cu moiety of the nanoparticle bound to a site that
straddles domains II. However, TiO2 nanoparticle docked with Lys
286 at subdomain II A which is referred as suldow site I. Both the
nanoparticle protrudes with aliphatic region at front end of the
pocket at respective domain. This interaction helps to compare the
Fig. 5. Graphical representation of HSA-TiO2 nanoparticle complex. Residues involved in the hydrophobic interactions are shown in graphical form.
Fig. 6. Aliphatic region of HSA-TiO2 nanoparticle complex. The surrounding residue
of HSA that forms grove with TiO2 NPs.
Table 1
Binding energy obtained for CuO nanoparticle HSA interaction and TiO2 nano-
particle HSA Interaction by molecular docking approach. Binding energy generated
is higher in case of CuO NPs as compared to TiO2 NPs HSA interaction.
TiO2 CuO
Binding energy 2.47 kcal mol1 1.64 kcal mol1
S. Chibber, I. Ahmad / Biochemistry and Biophysics Reports 6 (2016) 63–6766relative binding grove residues at suldow site I and II respectively
for each nanoparticle and has a large impact on only one side of
HSA for respective nanoparticle that could correspond to drug
binding site. Furthermore, in case of TiO2-HSA interaction extensiverearrangement of the H-bond network occurs between residues Arg
257, Ala 258, Ser 287, His 288, Leu 283, Ala 254, Tyr 150 with na-
noparticle and this may result in increase in pocket volume for drug
like azapropazone which are speciﬁc for suldow site I [13]. The
success rate of docking for region predicted for the binding in case
of both CuO np-HSA and TiO2 np-HSA interactionwas considered by
an observed binding energy as it was found to be ΔGo0.
The general anesthetic propofol has also been shown to bind to
Sudlow’s site II (subdomain IIIA) in a cavity that able to host the
diiodophenol ring of a thyroxine molecule as well [20]. The general
anesthetic halothane also binds to Sudlow's site II. Since, we have
also predicted that CuO nanoparticle also bind to Sudlow's site II i.e,
subdomain III A thus can be used with thyroxine in exploring the
pharmacokinetics, and may increase vulnerability of thyroxin in
blood stream after binding with serum albumin protein, subse-
quently, can also serve as inhibitor for thyroxine to bind with al-
bumin protein and to understand its mechanism more clearly.
However, TiO2 np bind to site I there-by can be use as competitive
inhibitor for phenylbutazone by competing at suldow site 1 and can
protrude in drug binding efﬁcacy. Moreover, indomethacin (IMN)
azapropazone (AZP) drug can bind to subdomain II A. studies have
shown that because of nanomaterials property large surface to
volume ratio they are used frequently in drug delivery system.
Considering TiO2 NPs binding mode with subdomain II A, TiO2 Nps
can be used as nanocomposite for indomethacin (IMN) as well as
with azapropazone (AZP) drug in a drug delivery system [12].
Subdomain III A in HSA has also been reported to possess es-
terase like activity (hydrolysis of p-nitrophenol esters) [21]. As
discussed CuO nanoparticle bind to subdomain III A thus binding
of these nanoparticles to this region may inﬂuence esterase like
activity of Serum albumin protein. Thus, CuO np can be variably
used with different alkaloids for its effectiveness by targeting es-
terase like activity of serum albumin protein [21].
The 4-Phenylbutyric acid (4-PBA) is a drug used in disease
conditions like type 2 diabetes, obesity and neurodegeneration
[22]. It alleviates endoplasmic reticulum stress by assisting protein
S. Chibber, I. Ahmad / Biochemistry and Biophysics Reports 6 (2016) 63–67 67folding. The molecular docking study on 4-PBA explores the
binding nature of 4-PBA with human serum albumin (HSA) and
reported that 4-PBA has high binding speciﬁcity to Suldow Site II
(subdomain IIIA). The suldow site II also knows as Fatty acid
binding site 3, (subdomain III A). We can say based on our analysis
that CuO nanoparticles bind to subdomain III A i.e fatty acid
binding site 3 thus CuO can also be study for drug delivery ap-
proach for 4-PBA in-order to understand its kinetics. Moreover,
CuO could also be applied with application like micelles formation
to overruled fatty acid binding potential with serum albumin
protein by targeting fatty acid binding site 3 in HSA protein.5. Conclusions
HSA comprises of three homologous domains (I, II, and III) that
assemble to form a cordate molecule. The hydrophobic pockets at
subdomains IIA and IIIA is the main regions of ligand interactionwith
IIIA having the highest afﬁnity for the interaction. In our study the
whole region of HSA was selected in order to predict binding of HSA
with CuO and TiO2 nanoparticle. We have exploited CuO nanoparticle
bind to site II, subdomain III A and TiO2 nanoparticle bind to site I
located at subdomain II A of HSA protein. Thus, it can be inferred that
both CuO and TiO2 nanoparticles showed HSA binding properties,
with TiO2 nanoparticle having a slightly higher afﬁnity towards HSA.
This is attributed on the basis of the binding energy which is less in
case of TiO2 nanoparticle as compared to CuO nanoparticle.Acknowledgements
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